Improvement in Retinal Capillary Rarefaction After Valsartan Treatment in Hypertensive Patients.

Journal of clinical hypertension (Greenwich, Conn.)

PubMedID: 27306560

Jumar A, Harazny JM, Ott C, Kistner I, Friedrich S, Schmieder RE. Improvement in Retinal Capillary Rarefaction After Valsartan Treatment in Hypertensive Patients. J Clin Hypertens (Greenwich). 2016;.
Decreased capillary density influences vascular resistance and perfusion. The authors aimed to investigate the influence of the renin-angiotensin receptor blocker valsartan on retinal capillary rarefaction in hypertensive patients. Retinal vascular parameters were measured noninvasively and in vivo by scanning laser Doppler flowmetry before and after 4 weeks of treatment with valsartan in 95 patients with hypertension stage 1 or 2 and compared with 55 healthy individuals. Retinal capillary rarefaction was determined with the parameters intercapillary distance (ICD) and capillary area (CapA). In hypertensive patients, ICD decreased (23. 4±5. 5 µm vs 21. 5±5. 6 µm, P<. 001) and CapA increased (1564±621 vs 1776±795, P=. 001) after valsartan treatment compared with baseline. Compared with healthy normotensive controls (ICD 20. 2±4. 2 µm, CapA 1821±652), untreated hypertensive patients showed greater ICD (P<. 001) and smaller CapA (P=. 019), whereas treated hypertensive patients showed no difference in ICD (P=. 126) and CapA (P=. 728). Therapy with valsartan for 4 weeks diminished capillary rarefaction in hypertensive patients.